GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Inventory-to-Revenue
Switch to:

Biogen (MEX:BIIB) Inventory-to-Revenue

: 0.56 (As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biogen's Average Total Inventories for the quarter that ended in Mar. 2023 was MXN24,650 Mil. Biogen's Revenue for the three months ended in Mar. 2023 was MXN44,396 Mil. Biogen's Inventory-to-Revenue for the quarter that ended in Mar. 2023 was 0.56.

Biogen's Inventory-to-Revenue for the quarter that ended in Mar. 2023 increased from Dec. 2022 (0.54) to Dec. 2022 (0.56)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biogen's Days Inventory for the three months ended in Mar. 2023 was 188.28.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biogen's Inventory Turnover for the quarter that ended in Mar. 2023 was 0.48.


Biogen Inventory-to-Revenue Historical Data

The historical data trend for Biogen's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventory-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.07 0.11 0.14

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Inventory-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.48 0.53 0.54 0.56

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Inventory-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biogen's Inventory-to-Revenue falls in comparison to its industry or sector. The grey bar indicates the Inventory-to-Revenue's extreme value range as defined by GuruFocus.



Biogen Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biogen's Inventory-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Inventory-to-Revenue (A: Dec. 2022 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2021 ) + Total Inventories (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )
=( (27724.671 + 26210.422) / 2 ) / 198340.607
=26967.5465 / 198340.607
=0.14

Biogen's Inventory-to-Revenue for the quarter that ended in Mar. 2023 is calculated as

Inventory-to-Revenue (Q: Mar. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2022 ) + Total Inventories (Q: Mar. 2023 )) / count ) / Revenue (Q: Mar. 2023 )
=( (26210.422 + 23090.025) / 2 ) / 44395.575
=24650.2235 / 44395.575
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biogen's Days Inventory for the three months ended in Mar. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2023 )/Cost of Goods Sold (Q: Mar. 2023 )*Days in Period
=24650.2235/11946.97*365 / 4
=188.28

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biogen's Inventory Turnover for the quarter that ended in Mar. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2023 ) / Average Total Inventories (Q: Mar. 2023 )
=11946.97 / 24650.2235
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biogen's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines